通过电 ?? 调节神经炎症:机制性见解和药理学协同作用
Salvador Quiroz-González1, Erika Elizabeth Rodríguez-Torres2, Ismael Jiménez-Estrada3
1Department of Acupuncture and Rehabilitation, State University of Ecatepec Valley, Ecatepec State of México, Mexico.
Current opinion in pharmacology
|September 21, 2025
概括
电针 (EA) 通过抑制促炎途径和促进抗炎信号来调节神经炎症. 这种神经调节技术显示出治疗神经退行性疾病的潜力,特别是与某些药物结合使用时.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 综合医学是一个整体的医学.
背景情况:
- 神经炎症是神经和神经退行性疾病的核心.
- 目前的药理疗法面临着诸如血脑屏障 (BBB) 穿透能力低下和副作用等挑战.
- 电针 (EA) 是一种新兴的神经免疫调节的辅助疗法.
研究的目的:
- 探索电 (EA) 的神经免疫调节机制.
- 评估EA作为神经退行性疾病的辅助疗法的潜力.
- 调查EA与药理学药物的协同作用.
主要方法:
- 审查EA对质激活,细胞因子释放和BBB完整性的影响.
- 分析EA的分子点,包括TLR4/NF-κB,NLRP3炎症酶,JAK2/STAT3和PI3K/Akt通路.
- 检查EA对微质极化和肠-大脑轴的影响.
主要成果:
- 它可以抑制促炎途径 (TLR4/NF-κB,NLRP3) 和增强抗炎信号 (JAK2/STAT3,PI3K/Akt).
- EA促进了向修复性M2微质细胞的转变,并调节了BBB的透性.
- EA与l-DOPA,塞利吉林,多尼佩西尔和米诺环素等药物产生协同作用,改善神经保护和减少炎症.
结论:
- EA有效调节神经炎症和神经免疫反应.
- 脑电学具有很大的潜力,可以纳入神经退行性疾病的临床策略.
- 了解EA的机制可以指导个性化的神经免疫干预,将EA和药物治疗结合起来.
相关概念视频
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:19Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...